{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T08:17:08Z","timestamp":1790410628452,"version":"4.1.0"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"am","delay-in-days":307,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008273","name":"Novartis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008273","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008486","name":"Schweizerische Multiple Sklerose Gesellschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008486","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016015","name":"Universit\u00e4tsspital Basel","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.msard.2019.01.044","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T06:31:38Z","timestamp":1548743498000},"page":"236-243","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"special_numbering":"C","title":["Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies"],"prefix":"10.1016","volume":"30","author":[{"given":"Lori","family":"Mayer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5509","authenticated-orcid":false,"given":"Ludwig","family":"Kappos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1231-4694","authenticated-orcid":false,"given":"Michael K.","family":"Racke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kottil","family":"Rammohan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0351-9639","authenticated-orcid":false,"given":"Anthony","family":"Traboulsee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen L.","family":"Hauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold","family":"K\u00f6ndgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Napieralski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhe","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry S.","family":"Wolinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.msard.2019.01.044_bib0001","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/11585960-000000000-00000","article-title":"Incidence of infusion-associated reactions with rituximab for treating multiple sclerosis: a retrospective analysis of patients treated at a US centre","volume":"34","author":"Brown","year":"2011","journal-title":"Drug Saf."},{"issue":"14","key":"10.1016\/j.msard.2019.01.044_bib0002","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL","volume":"69","author":"Calabresi","year":"2007","journal-title":"Neurology"},{"issue":"9856","key":"10.1016\/j.msard.2019.01.044_bib0003","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","article-title":"Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial","volume":"380","author":"Cohen","year":"2012","journal-title":"Lancet"},{"issue":"9856","key":"10.1016\/j.msard.2019.01.044_bib0004","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/S0140-6736(12)61768-1","article-title":"Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial","volume":"380","author":"Coles","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2019.01.044_bib0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.msard.2018.11.027","article-title":"Reduction in ocrelizumab-induced infusion reactions by a modified premedication protocol","volume":"27","author":"Conte","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2019.01.044_bib0006","series-title":"32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)","article-title":"Infusion-related reactions with ocrelizumab in relapsing-remitting multiple sclerosis and primary progressive multiple sclerosis","author":"de Seze","year":"2016"},{"key":"10.1016\/j.msard.2019.01.044_bib0007","article-title":"Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies","author":"Dunn","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2019.01.044_bib0009","unstructured":"Genentech, Inc. OCREVUSTM [ocrelizumab] full prescribing information, 2017."},{"issue":"3","key":"10.1016\/j.msard.2019.01.044_bib0010","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.msard.2019.01.044_bib0011","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2019.01.044_bib0012","unstructured":"Hendricks R, Song A, Chung S, Wang Q, Chin P, Garren H. Immunogenicity with repeated dosing of ocrelizumab in patients with multiple sclerosis. 2016."},{"issue":"5","key":"10.1016\/j.msard.2019.01.044_bib0013","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.12-5-601","article-title":"Management and preparedness for infusion and hypersensitivity reactions","volume":"12","author":"Lenz","year":"2007","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.msard.2019.01.044_bib0014","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1586\/eci.10.90","article-title":"Acute infusion reactions induced by monoclonal antibody therapy","volume":"7","author":"Maggi","year":"2011","journal-title":"Expert Rev. Clin. Immunol."},{"key":"10.1016\/j.msard.2019.01.044_bib0015","unstructured":"Mayer L, Kappos L, Racke MK, et\u00a0al. Infusion-related reactions with ocrelizumab: pooled analysis of the open-label extension of the phase III, interferon beta-1a-controlled OPERA studies. 2017."},{"issue":"3","key":"10.1016\/j.msard.2019.01.044_bib0016","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.01.044_bib0017","series-title":"Common Terminology Criteria for Adverse Events v4.0. NCI, NIH, DHHS","year":"2009"},{"key":"10.1016\/j.msard.2019.01.044_bib0018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaip.2016.12.001","article-title":"Current knowledge and management of hypersensitivity reactions to monoclonal antibodies","volume":"5","author":"Picard","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"9","key":"10.1016\/j.msard.2019.01.044_bib0019","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2019.01.044_bib0020","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa044396","article-title":"Natalizumab plus interferon beta-1a for relapsing multiple sclerosis","volume":"354","author":"Rudick","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2019.01.044_bib0021","series-title":"2016 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC)","article-title":"Infusion-related reactions with ocrelizumab in the phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","author":"Selmaj","year":"2016"},{"key":"10.1016\/j.msard.2019.01.044_bib0022","series-title":"2nd Congress of the European Academy of Neurology (EAN)","article-title":"Infusion-related reactions with ocrelizumab in the phase III double-blind, double-dummy, interferon beta-1a-controlled OPERA I and OPERA II studies","author":"Selmaj","year":"2016"},{"issue":"7","key":"10.1016\/j.msard.2019.01.044_bib0023","article-title":"Immunogenicity of alemtuzumab treatment in relapsing-remitting multiple sclerosis (RRMS) patients in the CARE-MS II study","volume":"80","author":"Sorensen","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2019.01.044_bib0024","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1212\/WNL.0000000000000125","article-title":"Safety and efficacy of ofatumumab in relapsing-remitting multiple sclerosis: a phase 2 study","volume":"82","author":"Sorensen","year":"2014","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819300446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:38Z","timestamp":1761900218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819300446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":23,"alternative-id":["S2211034819300446"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.044","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.01.044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}